- Noxopharm (NOX) is granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy
- The patent allows dosages of chemotherapy to be lowered to safer levels through the company’s drug candidate without compromising its anti-cancer effectiveness
- Noxopharm says it’s confident the combination can deliver an even stronger anti-cancer response
- The patent in Australia and Europe remains valid until 21 April 2037, while US patents remain under examination
- Noxopharm shares climbed 2.80 per cent, trading at 55.5 cents
Noxopharm (NOX) has been granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy.
Veyonda is the company’s first pipeline drug candidate, which is currently in phase 2 clinical trialling.
The company received notices of allowance from both the Australian and European patent offices for claims covering the use of the active ingredient in Veyonda, idronoxil, as a chemo-enhancing drug.
Pre-clinically, idronoxil increases the cancer-killing effect of all common chemotherapies up to magnitudes exceeding 1000-times.
The patent, entitled ‘chemotherapy improvements’, allows dosages of chemotherapy to be lowered to safer levels through the use of Veyonda, without compromising its anti-cancer effectiveness.
Noxopharm said it’s confident the combination can deliver an even stronger anti-cancer response, at the same time as offering the safer benefit.
Noxopharm CEO, Graham Kelly, explained a high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side effects or are too ill, elderly or unwilling to start chemotherapy.
“That is the gap that we see Veyonda filling by allowing the patient to still gain the benefit of the chemotherapy but at dosages that are much better tolerated,” Mr Kelly said.
“Allowance of these claims is a major milestone in the company’s aim to see Veyonda become a standard of care companion drug in oncology for chemotherapy, radiotherapy and immunotherapy.”
The company said with its radiotherapy and immunotherapy patent positions looking strong, the new allowances represent an important step, and hopes it will be attractive to major pharma companies with strong chemotherapy drug portfolios.
The patent in Australia and Europe remains valid until 21 April 2037, while US patents remain under examination.
Noxopharm shares climbed 2.80 per cent, trading at 55.5 cents at 2:43 pm AEDT.